GST Council to Consider Classifying Overseas Clinical Trials as Exports
The GST Council is set to discuss treating clinical trials conducted in India for foreign sponsors as export services, a move that could boost the country's contract research sector.
Proposals slated for the upcoming GST Council meeting would label clinical testing and analysis carried out for overseas sponsors as exports. The plan also includes input tax credit relief on free samples and expired drugs, and a 90% refund of accumulated credit to ease working-capital pressure for pharmaceutical companies. If approved, the changes aim to strengthen India's contract research and pharmaceutical services industry.
Why it matters
Classifying overseas clinical trials as exports could lower costs for drugmakers and attract more foreign research projects to India.
How the sides frame it
LOW AGREEMENTCenter coverage frames the proposal as a technical alignment of export definitions with actual service flows through overseas branches, while right-leaning coverage frames it as a move to classify overseas clinical trials as exports and boost the pharmaceutical industry.
CENTER
Centrist coverage presents the GST Council's move as a clarification and alignment of export rules to match how services are currently exported via overseas branch offices.
RIGHT
Right-leaning coverage portrays the GST Council's proposal as a targeted effort to label overseas clinical trials as exports and provide tax relief to strengthen India's pharma and contract research sector.
The right emphasises
- label clinical testing and analysis carried out for overseas sponsors as exports
- input tax credit relief on free samples and expired drugs, and a 90% refund of accumulated credit
- aim to strengthen India's contract research and pharmaceutical services industry
In this story
